Business Description
Anebulo Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0345691036
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.83 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate | -13.86 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.56 | |||||
9-Day RSI | 39.71 | |||||
14-Day RSI | 40.29 | |||||
6-1 Month Momentum % | -29.53 | |||||
12-1 Month Momentum % | -7.25 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.32 | |||||
Quick Ratio | 5.32 | |||||
Cash Ratio | 5.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -107.83 | |||||
ROA % | -96.08 | |||||
ROIC % | -1444.58 | |||||
ROCE % | -108.09 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 9.22 | |||||
Price-to-Tangible-Book | 8.32 | |||||
EV-to-EBIT | -5.24 | |||||
EV-to-EBITDA | -5.24 | |||||
EV-to-FCF | -4.59 | |||||
Price-to-Net-Current-Asset-Value | 9.29 | |||||
Price-to-Net-Cash | 9.88 | |||||
Earnings Yield (Greenblatt) % | -19.08 | |||||
FCF Yield % | -16.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Anebulo Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.342 | ||
Beta | -0.05 | ||
Volatility % | 38.87 | ||
14-Day RSI | 40.29 | ||
14-Day ATR (€) | 0.076608 | ||
20-Day SMA (€) | 1.704 | ||
12-1 Month Momentum % | -7.25 | ||
52-Week Range (€) | 1.57 - 2.88 | ||
Shares Outstanding (Mil) | 25.93 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Anebulo Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Anebulo Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Anebulo Pharmaceuticals Inc Frequently Asked Questions
What is Anebulo Pharmaceuticals Inc(FRA:214)'s stock price today?
When is next earnings date of Anebulo Pharmaceuticals Inc(FRA:214)?
Does Anebulo Pharmaceuticals Inc(FRA:214) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |